Clinical Trial TitleA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (RIN-PF-301)
National Clinical Trial Number:NCT04708782
Clinical Trial Protocol Description:
The purpose of this study is to see how well inhaled treprostinil works in participants with idiopathic pulmonary fibrosis (IPF) and to gather information on how safe it is.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are at least 40 years of age.
- Have a diagnosis of IPF.
- If taking pirfenidone or nintedanib, are on a stable and optimized dose for ≥30 days.
- Are willing and likely to be cooperative with protocol requirements, including attending all study visits.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.